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Abstract
Common diseases like diabetes, hypertension, and atrial fibrillation are probable risk factors for dementia, suggesting
that their treatments may influence the risk and rate of cognitive and functional decline. Moreover, specific therapies
and medications may affect long-term brain health through mechanisms that are independent of their primary
indication. While surgery, benzodiazepines, and anti-cholinergic drugs may accelerate decline or even raise the risk of
dementia, other medications act directly on the brain to potentially slow the pathology that underlies Alzheimer’s and
other dementia. In other words, the functional and cognitive decline in vulnerable patients may be influenced by the
choice of treatments for other medical conditions. Despite the importance of these questions, very little research is
available. The Alzheimer’s Drug Discovery Foundation convened an advisory panel to discuss the existing evidence and
to recommend strategies to accelerate the development of comparative effectiveness research on how choices in the
clinical care of common chronic diseases may protect from cognitive decline and dementia.
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Background
Cognitive impairment diagnosed as dementia, mild
cognitive impairment (MCI), and/or mild neurocognitive
disorder (mNCD) represents one of the most feared
conditions in the United States and one of the most
common reasons to enter a nursing home. In North
America alone, the financial cost of dementia was esti-
mated at $270 billion for 2015 with $61 billion in direct
medical costs [1]. The burden from MCI is more diffi-
cult to quantify [2] but profound effects on quality of
life, productivity, and health are likely [3, 4]. Cognitive
aging itself, while not a diagnosed medical condition,
can influence quality of life and can be protected against
through a variety of steps outlined in a recent Institute
of Medicine report [5]. The consequences of cognitive
decline pervade other aspects of health. For example,
patients with cognitive impairment are less likely to
comply with prescribed treatments and more likely to
require hospitalization or experience treatment-related
adverse events.
The factors that contribute to the risk and progres-
sion of MCI and dementia are varied and uncertain
even for Alzheimer’s disease, the most extensively
researched cause of dementia [6]. Several different
trajectories appear to lead to the clinical phenotype of
Alzheimer’s disease, with distinct molecular causes
and risk factors as well as different patterns of pro-
gression [7] as reflected by the inability to generate a
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single risk prediction model for population-based
settings [8]. Combinations of neuropathology are
common and probably contribute synergistically to
cognitive impairment (e.g. [9]).
For many patients, the comorbidities and the corre-
sponding medical care may contribute to their long-
term risk of cognitive and functional decline. These fac-
tors, in turn, may provide opportunities for precision
medicine to tailor patient treatment according to their
risk profile.
In 2015, the Alzheimer’s Drug Discovery Foundation
convened an advisory panel on “The Prevention of
Dementia and Mild Cognitive Impairment as Variables
to Consider In the Comparative Effectiveness of Treat-
ments for Common Chronic Conditions.” The panel
included representatives of the American Diabetes Asso-
ciation and the American Heart Association as well as
experts from industry, academic and government re-
search institutes, and the Patient-Centered Outcomes
Research Institute (PCORI).
The consensus perspective was that clinical care of
chronic diseases and comorbidities can likely influence
cognitive decline, particularly in high-risk patients, but
the existing evidence base for specific treatment
choices is weak and conflicted. The meeting discussions
were formulated into five recommendations for re-
searchers, clinicians, and other stakeholders to advance
research on how clinical treatment options may influ-
ence long-term cognitive decline. The views expressed
are those of the authors and not their organizations.
Prevalent diseases are risk factors for cognitive decline
and dementia
Several major chronic diseases are risk factors for
dementia, linked by both epidemiology and biological ra-
tionale, suggesting that their clinical management might
influence cognitive decline.
Hypertension in mid-life associates with a higher risk
of dementia (reviewed in [10]). In the SYST-EUR trial,
nitrendipine reduced the risk of Alzheimer’s or vascular
dementia by about 50 % [11]. In the PROGRESS trial, an
angiotensin converting enzyme (ACE) inhibitor reduced
the risk of cognitive decline by 19 % largely because of a
reduced risk of recurrent stroke [12]. Other trials have
not reported such benefits [13], likely because of differ-
ences in study design and patient population (reviewed
in [10]). In some cases, the null result might have been
due to outcome ascertainment bias such as in the SHEP
trial, in which patients assigned to placebo were 24–
60 % more likely to miss their outcome assessment [14].
Atrial fibrillation has also been associated with de-
mentia. This relationship is independent of stroke
(reviewed by [15]) and stronger with longer durations
of atrial fibrillation [16]. A causative relationship is
possible through repetitive microemboli or microbleeds
but research is needed to show whether choices in the
treatment of atrial fibrillation can influence dementia
risk [15].
Type 2 diabetes mellitus (T2DM) is also associated
with a higher risk of Alzheimer’s (reviewed in [17, 18]).
Insulin resistance and glucose dysmetabolism in the
brain may directly drive Alzheimer’s neuropathology and
increase the risk of cerebral infarcts that can in turn
contribute to the manifestation of dementia (reviewed in
[17]). Whether the clinical management of diabetes can
influence cognitive decline is not yet certain. In the
ACCORD-MIND trial, intensive versus standard gly-
cemic control failed to protect against cognitive de-
cline over 40 months but did result in a higher total
brain volume [19].
Other diseases linked to cognitive decline include
sleep-disordered breathing [20], heart failure [21], and
chronic obstructive pulmonary disease [22]. More re-
search is needed to establish whether these relationships
are causal and, most importantly, if and how their clin-
ical management can influence cognitive decline. Frailty
and the accumulation of health deficits with old age [23]
have also been linked to a higher risk of dementia, serv-
ing as an important reminder that biological vulnerabil-
ities caused by aging underlie a suite of serious and
common age-related ailments.
Specific medical treatments may influence the risk of
cognitive decline
Several common medical treatments are suspected to in-
crease the risk of long-term cognitive decline. Cumula-
tive anti-cholinergic drug burden has been associated
with a dose-dependent increase of incident dementia as
high as 54 % [24]. Similar risks have been reported for
benzodiazepines and proton pump inhibitors [25].
Surgery can cause delirium or cognitive dysfunction in
vulnerable patients which, in turn, associates with a
higher risk of poor functional outcomes including de-
mentia (reviewed in [26]). An ongoing controversy is
whether surgery can cause persistent cognitive decline
or simply unmask an underlying neurodegenerative ill-
ness (e.g. [27]). Even if the latter is true, earlier manifest-
ation of progressive dementia is a significant concern.
While some treatments may increase the risk or the
rate of cognitive decline, others may reduce it. Roughly
2 million cases of Alzheimer’s disease have been attrib-
uted to physical inactivity, smoking, and mid-life obesity
[28], suggesting that lifestyle modifications for cardio-
metabolic disease may profoundly protect the brain
(reviewed in [29]). In clinical trials, cognitive function in
the elderly has been improved through diet [30] or a
multi-faceted intervention of lifestyle, diet, and vascular
risk management [31]. These studies must be followed
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with longer and larger studies to evaluate effects on de-
mentia risk.
There is intense interest in the question of whether
specific drugs can be repurposed to treat or prevent neu-
rodegenerative disease. Table 1 lists clinical trials that
are underway to test whether specific drugs might re-
duce the risk or slow the progression of dementia or
MCI through direct effects in the brain that are inde-
pendent of their approved indications for treating high
blood pressure or blood glucose. If these drugs do
indeed slow neurodegeneration, a promising strategy to
reduce dementia risk would be to manage hypertension
or diabetes in high-risk patients with a clinically appro-
priate drug that has additional beneficial effects on the
brain. Examples of potential treatment comparisons are
described in Table 2.
The examples provided are not intended to compre-
hensively review the available data but rather to high-
light the many ways through which common clinical
care decisions might slow cognitive decline or reduce
the risk of dementia. More research is needed to guide
clinical care. Below, we recommend five general ap-
proaches to enable or bolster research that could create an
evidence base to guide clinical care to mitigate the risk of
cognitive decline or dementia in vulnerable patients.
Main text
Recommendation 1: researchers should utilize
complementary study designs that incorporate patients
at high risk for cognitive decline
The study of real-world populations is central to CER
yet particularly challenging for research on cognitive de-
cline. Patients with advanced age or comorbidities, who
are highly vulnerable to cognitive decline, are rarely in-
cluded in research (e.g. [32]). Even in geriatrics, cogni-
tively impaired patients are rarely recruited for clinical
research on other conditions [33] and those that develop
impairment during the trial are likely to drop out before
their outcome can be assessed [14]. Most of the clinical
research that has been done on other health conditions
Table 1 Examples of clinical trials testing neuroprotective properties of an anti-hypertensive or anti-diabetic drug
Drug Class Primary clinical
use
Trials underway to evaluate the use to treat
or prevent dementia or cognitive decline
Putative primary
mechanism of action
Estimated
completion
Nilvadipine Calcium channel
blocker
Hypertension NILVAD Phase III trial evaluating if this
calcium-channel blocker can improve cognitive
function in mild-moderate Alzheimer’s disease
(NCT02017340)
Beta-amyloid clearance
and cortical perfusion
2017
Telmisartan
versus
Perindopril
ARB versus ACE
inhibitor
Hypertension SARTAN-AD Phase II head-to-head comparison
of perindopril and telmisartan in Alzheimer’s
patients with hypertension, using brain atrophy
as an experimental surrogate marker
(NCT02085265)
Beta-amyloid production
and catabolism
2017
Candesartan or
Losartan
ARB Hypertension A Phase II trial with candesartan in MCI
(NCT02646982) and Losartan in Alzheimer’s
(ISRCTN93682878)
Neurovascular injury, blood-
flow, beta-amyloid pathways
2021 & 2017
Metformin Biguanide Diabetes A Phase II in Alzheimer’s (NCT02409238) and
a Phase II trial in MCI (NCT01965756) are underway
Restore insulin signaling in
the brain
2017 & 2016
Pioglitazone,
mini-dose
Thiazolidinedione Diabetes but at
a different dose
Phase 3 trial testing a very low-dose formulation
of pioglitazone to reduce the risk MCI due to
Alzheimer’s (NCT01931566)
Metabolism and
inflammation
2019
Liraglutide Incretin mimetic
(GLP-1 agonist)
Diabetes Two Phase II trials underway or recently
completed in Alzheimer’s (NCT01843075;
NCT01469351). A third trial is underway in aging
adults at high risk of dementia (NCT02140983)
and a fourth Phase III trial is underway on
cognitive dysfunction in major depressive
disorder or bipolar disorder (NCT02423824)
Restore insulin signaling in
the brain to slow Alzheimer’s
pathology
2015–2017
Exenatide
(Exendin-4)
Incretin mimetic
(GLP-1 agonist)
Diabetes A Phase 2 safety trial in patients with Alzheimer’s
or mild cognitive impairment with secondary
outcomes of behavioral and cognitive
performance, ADAS-cog and CDR, and biomarkers
related to Alzheimer’s disease and dementia
(NCT01255163)
Restore insulin signaling in
the brain to slow Alzheimer’s
pathology
2018
Examples of clinical trials underway to evaluate whether a drug approved for hypertension or diabetes could be repurposed to treat or prevent Alzheimer’s
disease or cognitive impairment. Many other trials have already been completed. In all cases, the putative mechanism of action involves a direct effect on the
brain rather than an indirect effect through treatment of the primary indication. Other repurposing efforts are underway with drugs approved for depression,
epilepsy, and erectile dysfunction. Very few studies are designed for CER, i.e. to compare the cognitive outcomes from treatments that are clinically equivalent for
their currently approved indication
ACE angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, MCI mild cognitive impairment
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cannot therefore accurately inform how those treatments
affect cognitive decline and dementia risk even if those
outcomes were recorded.
Another challenge is the heterogeneous nature of
dementia, as described above. The treatments that re-
duce the risk of decline and the trials capable of de-
tecting a benefit may succeed in one population but
not another. To overcome these challenges, a combin-
ation of study designs with complementary strengths
and weaknesses that include patients at high risk of
cognitive decline is needed.
Pragmatic Phase III randomized controlled trials
(RCTs) are most likely to influence clinical care but
there are limits on our ability to fund and carry out
multiple randomized head-to-head comparisons with
sufficient power and follow-up. Short-term RCTs rarely
have sufficient power to detect clinically meaningful
change in cognitive decline and related function but
shorter trials can use biomarker endpoints to validate
the putative disease-modifying effects of treatments.
For example, a pilot trial reported that hypertension
management with nilvadipine versus amlodipine might
improve cerebral blood flow in patients with MCI des-
pite similar effects on blood pressure [34]. Currently, a
trial is underway at the Sunnybrook Research Institute
in Canada to compare hypertension management with
telmisartan versus perindopril in patients with comor-
bid Alzheimer’s, looking at global brain atrophy over
one year (Table 1). Although these biomarkers are not
validated as surrogate markers, these exploratory trials
can raise confidence for larger and longer trials on
patient-centered outcomes.
Observational study designs are essential tools for
comparative effectiveness research (CER) [35] and de-
mentia prevention research [36, 37] that provide win-
dows into real-world heterogeneous patient populations.
These studies are at high risk of confounding by indica-
tion and other bias but robust associations with cogni-
tive decline can still inform hypotheses and guide
clinical trial design.
Table 2 Examples of potential questions for comparative effectiveness research
Patient population Treatment comparisons Putative mechanisms in the brain Clinical research
Hypertensive
patients at high
risk of cognitive
decline
Telmisartan versus other
ARBs versus centrally acting
ACEi versus non-centrally
acting ACEi
Polymorphisms in ACE have been linked to
Alzheimer’s disease [60] but whether central
ACE inhibition will protect or harm is unclear.
ACEi but not ARBs might accelerate
beta-amyloid pathology by blunting ACE
activity on non-angiotensin pathways and
by inhibiting AT2 and AT4 receptors. One
ARB in particular, telmisartan, has additional
activity on PPAR gamma that might protect
against neurodegeneration [61]
A network meta-analysis concluded that
ARBs had more benefit on cognition than
ACEi drugs (adjusted effect size 0.47 +/– 0.17,
p = 0.04) [62]. Yet hypertension management
with centrally acting versus non-centrally acting
ACEi was associated with 25 % slower functional
decline in Alzheimer’s patients [63]. A Phase II
trial is underway to compare telmisartan to
perindopril in patients with comorbid
hypertension and Alzheimer’s (Table 1).
Additional comparisons are needed
Hypertensive
patients at risk of
cognitive decline
Amlodipine or
nifedipine versus other
DHP CCBs
Most DHP CCBs are likely to penetrate the
brain except for amlodipine. Nilvadipine and
nitrendipine but not amlodipine decreased
beta-amyloid accumulation and blunted
apoptosis in a mouse model of Alzheimer’s.
DHP CCBs varied in their capacity to increase
amyloid clearance from the brain [64]. Effects
on the brain may vary depending on their
selectivity for different calcium channels [65]
In a small trial in hypertensive patients with MCI,
nilvadipine versus amlodipine slowed cognitive
decline and improved cerebral blood flow despite
similar effects on blood pressure [34]. Nitrendipine
and nimodipine, have clinical data to suggest utility
for the prevention or treatment of dementia,
respectively, while nifedipine was associated with
an increased risk of cognitive decline (reviewed in
[64]). A Phase III trial is underway to test nilvadipine
as a treatment for Alzheimer’s (Table 1)
Diabetes patients
at risk of cognitive
decline
Centrally penetrant versus
non-penetrant GLP-1
agonists
GLP-1 agonists have been shown to protect
against hippocampal synapse loss, lower
beta-amyloid pathology and related damage,
reduce neuroinflammation, and promote
neurogenesis. While exenatide, liraglutude,
and lixisenatide cross the blood–brain barrier,
albiglutide and dulaglutide are large proteins
unlikely to reach the brain [18]
Treatment with liraglutide blocked decline in
cerebral glucose metabolism over 6 months in
Alzheimer’s patients in a Phase II trial [66].
Additional trials are underway to repurpose these
drugs to treat cognitive impairment (Table 1) but
not to compare cognitive outcomes of CNS-
penetrant versus non-penetrant GLP-1 agonists for
diabetes treatment
Diabetes patients
with or without
comorbid
dementia
Choice of drugs to
minimize the risk of severe
hypoglycemia
Severe hypoglycemia can trigger acute
cognitive impairment and possibly accelerate
long-term cognitive decline [67]. The choice
of drugs used to manage diabetes may alter
the risk of severe hypoglycemia in some
patients
Nursing home patients with both dementia and
diabetes had up to 8× higher risk of severe
hypoglycemia when treated with sulphonylurea
instead of insulin analogs [68]. More research is
needed on how the choice of drugs alters risk in
diverse patient populations
Examples of potential questions for comparative effectiveness research to examine whether the choice of clinically equivalent treatments for a given disease
indication could influence the risk or rate of cognitive decline in high-risk patients
ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, DHP dihydropyridine
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There are several examples of the use of electronic
health records and related databases for exploratory
questions. The use of angiotensin receptor blockers
(ARBs) compared to other cardiovascular drugs was as-
sociated with a 24 % lower risk of incident dementia in
the US Veteran Affairs database [38]. The use of proton
pump inhibitors was associated with an increased risk
of all-cause dementia (HR 1.33; 95 % CI 1.04–1.83)
and a 44 % increased risk of Alzheimer’s disease from
a German database on primary care patients (HR
1.44; 95 % CI 1.01–2.06) [25]. These exploratory asso-
ciations should be followed up with additional obser-
vational studies to confirm the association and inform
the design of RCTs.
Recommendation 2: incorporate cognitive assessment of
high-risk individuals into routine clinical evaluations and
electronic health records
In order to learn whether specific clinical care decisions
influence cognitive decline, better recognition and
reporting of cognitive function is needed in clinical set-
tings particularly for patients at risk of cognitive decline
because of comorbidities, frailty, age, genetics, or family
history. Between 27 % and 81 % of cases of cognitive im-
pairment are not currently recognized in primary care
[39]. When a patient is diagnosed, they often have fairly
advanced impairment with little if any objective data
showing the trajectory of development of their impair-
ment over time.
Some groups have recommended widespread screen-
ing for MCI and/or dementia (e.g. [39–41]) while others
have called for research to prove that such screening
improves patient outcomes [42]. While this debate con-
tinues, a parallel consideration is annual cognitive test-
ing that informs clinical care even if it not used for
diagnostic screening.
Objectively measured cognitive ability has been rec-
ommended as an important variable to inform the clin-
ical care of geriatric patients with diseases like diabetes
[43], cancer [44], and heart failure [45]. Routine cogni-
tive evaluations can identify patients who might need
additional medication reminders or other treatments for
anxiety, depression, insomnia, polypharmacy, alcoholism,
or drug abuse. They can also create a longitudinal record
to help inform prognosis in later years if the patient or
their family reports subjective cognitive impairment.
Importantly for this discussion, regular cognitive evalua-
tions can create a longitudinal record of cognitive as-
sessments in real-world patient populations which could
inform CER on which treatments associate with better
or worse cognitive trajectories in which patients. A var-
iety of neuropsychological tests are suitable for general
practice, with strengths and weaknesses reviewed else-
where [39, 40].
Recommendation 3: in comparative effectiveness trials,
incorporate outcomes on dementia incidence, cognitive
decline, or neurodegeneration
One strategy to increase the feasibility of CER on de-
mentia risk or cognitive decline is to embed secondary
outcomes in trials designed for other conditions. Several
examples demonstrate that this can be done successfully.
A sub-study of the ACCORD T2DM trial compared the
effects of intensive versus standard blood glucose con-
trol on cognitive decline and brain atrophy [19]. The
SPRINT trial, comparing intensive versus less intensive
control of systolic blood pressure, was stopped early due
to a significant reduction in the primary cardiovascular
outcome [46]. For modest incremental cost, the trial also
included assessment of all-cause dementia incidence,
global cognitive decline, and MRI-measured changes in
brain structure [47], with results yet to be reported.
A major concern with this strategy is outcome ascer-
tainment bias [14]. Unlike major cardiovascular end-
points, cognitive outcomes cannot be readily captured
from medical databases for patients who fail to return to
the research clinic. Trial methods can be adapted, how-
ever, as achieved in the Ginkgo Evaluation of Memory
Study [48]. Another issue is that trials may be stopped
early because of emergence of clear differences in the
primary outcome (e.g. [46]). Extended follow-up may be
needed to ascertain differences in cognitive outcomes
that may take longer to emerge.
More recently in the Alzheimer's disease field, there
has been a change in emphasis to “slow progression” of
the disease to “prevent” or “delay” the onset of the dis-
ease itself. This implies the need to rethink traditional
study designs, including whether cognitive endpoints are
the most suitable ones for such studies. As such studies
tend to be more like epidemiological studies, “time to
event” may be more suitable than a cognitive test, par-
ticularly since cognitive changes in a “prevention” setting
tend to be small/subtle (much less the functional
changes, which are even more subtle), though it is not
yet clear which outcomes are best for such studies.
Recommendation 4: develop, validate, and standardize
practical and acceptable methods for frequent
assessment of cognition and function
Cognitive function varies on a daily, even hourly basis due
to sleep impairment, alcohol or nicotine use, emotional or
physical status, and other variables. Similar variation exists
for quality of life and activities of daily living. This variabil-
ity weakens the power to detect meaningful change with
infrequent, intermittent assessments.
Neuropsychiatric testing deployed on consumer-
devices has the potential to lower costs and increase the
capacity of frequent assessment, particularly with data
passively collected from routine patient behavior [49].
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For example, a patient’s conversations might be recorded
and processed with automated speech-analysis software
to detect the changes in verbal fluency and syntactic
complexity that may be symptomatic of MCI (reviewed
in [49]). An unobtrusive home-monitoring system can
measure parameters of activity such as gait deficits,
stride variability, and functional activities of daily living
[50]. A different approach adopted by Akili Interactive
Labs, Inc. is to design assays that entertain patients and
thereby encourage more frequent assessment.
These technologies may provide statistical power that
is not possible with current clinical instruments for ac-
tivities of daily living or cognitive ability. For example,
an estimated 80 % fewer patients would be required to
detect a change in behavior using the unobtrusive home
monitoring system mentioned above compared to con-
ventional annual neuropsychological testing [51]. It may
also provide the basis for collecting the “real-world” evi-
dence being sought by the 21st Century Cures Act.
The rapid evolution of technology creates opportun-
ities but also challenges. The ways in which data are col-
lected, anonymized, and aggregated will need to be
standardized before becoming widely adopted in clinical
research. Developers will need to define and demon-
strate the context of use for a given assessment tool (e.g.
prognosis, diagnosis, rate of decline) and the applicabil-
ity of the test to different populations (e.g. the influence
of language, culture, and disease state). As with other
types of ever-expanding data collected on individual citi-
zens, careful attention will be needed to guard against
risks to privacy, individual rights, and ethical abuse.
Recommendation 5: explore innovations in policy and
funding to encourage healthcare providers and
pharmaceutical companies to engage in comparative
effectiveness research
The scope of CER on cognitive decline will be severely
limited without investment and participation by organi-
zations outside of academic and government settings. In
theory, a drug would have a market advantage if its use
was shown to yield a lower risk of long-term cognitive
decline. In practice, however, companies have little com-
mercial incentive to pursue either CER [52] or repurpos-
ing of products for high-risk indications like dementia
[53]. Policy changes may help to incentive industry, for
example with an increased duration of data exclusivity
after approval of a new indication [53]. Alternatively, the
need for industry investment might be reduced by strat-
egies to lower the cost of CER and repurposing, for ex-
ample with preliminary or staged approval for a new
indication followed by post-approval pharmacovigilance
to confirm safety and efficacy [53].
Healthcare providers may similarly lack incentive to par-
ticipate in CER, which limits the potential to understand
real-world patient care using electronic medical records
and related databases [52]. Providers need resources, re-
imbursement, and training to evaluate patient cognition
and to understand the potential relationships between
clinical care and cognitive decline. They also need compel-
ling evidence that cognitive assessment improves patient
care without slowing provider productivity or raising
costs. Improved communication between researchers and
frontline healthcare providers could also improve the clin-
ical relevance of CER experimental design [54].
Conclusions
Over the past decade, CER has received more and more
attention in the United States and elsewhere. Patients,
families, healthcare providers, and payers increasingly
ask which treatments have the best benefit versus harm
ratio for a given patient. As this research advances,
we recommend increased assessment of cognitive de-
cline and the risk of dementia or MCI in CER stud-
ies. These outcomes are central to patient interests,
quality of life, medical care, and societal costs. They
are also likely to be influenced in profound ways by
routine clinical care decisions.
Many challenges exist in the design, implementation, and
funding of such research. Nevertheless, creative solutions
exist and resources for CER (e.g. PCORI) may be leveraged
to meet this need. Stakeholders across the spectrum of pa-
tients, providers, payers, researchers, and regulators can all
play a role in accelerating the development of an evidence
base so that clinicians and patients can learn whether the
management of their existing conditions can influence the
risk of cognitive decline and dementia.
CER in older people is a particular challenge because
the vulnerabilities caused by aging often lead to comorbid
chronic and acute diseases and ailments such as frailty
that impair quality of life and function. Indeed, frailty and
the accumulation of health deficits with old age have
themselves been linked to a higher risk of dementia [23,
55]. In these vulnerable populations, it can be challenging
if not impossible to compare the full breadth of clinical
benefit versus harm of diverse treatment options. Some
therapeutics, however, may alter specific aspects of aging
biology either through direct effects [56] or indirect effects
via the management of comorbidities linked to accelerated
aging (e.g. [57–59]). In order to assess which therapies
have the best harm versus benefit ratio in older people,
there is a strong need for defined and validated independ-
ent measures of elements of aging that affect morbidity
that could be evaluated more efficiently than the incidence
of numerous single clinical diseases. The rate of decline in
certain domains of cognitive function (e.g. language, ex-
ecutive function) could be one of several components of
such a screen for independent measures of morbidity as-
sociated with aging.
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